Based on the information provided, I was unable to find specific evidence regarding protein modifications during Lipitor (atorvastatin) regulated lipid absorption. However, I can share some general information about Lipitor and lipid absorption that may be helpful.

Lipitor is a statin medication used to lower cholesterol levels in the blood. It works by inhibiting HMG-CoA reductase, an enzyme that plays a crucial role in the production of cholesterol in the liver [1]. By reducing cholesterol production, Lipitor helps the liver to increase the number of LDL receptors on its surface, which in turn promotes the removal of LDL (bad) cholesterol from the bloodstream [1].

While there is no direct evidence of protein modifications during Lipitor-regulated lipid absorption, it is well-established that proteins play a vital role in lipid absorption. For instance, Niemann-Pick C1-like 1 (NPC1L1) is a protein found in the small intestine that facilitates the absorption of dietary cholesterol [2]. Ezetimibe, another cholesterol-lowering medication, works by inhibiting NPC1L1, thereby reducing cholesterol absorption [3].

In summary, while there is no specific information available about protein modifications during Lipitor-regulated lipid absorption, proteins are known to play a significant role in lipid absorption. Lipitor functions by inhibiting HMG-CoA reductase, reducing cholesterol production, and promoting LDL cholesterol removal from the bloodstream.

Sources:
[1] Mayo Clinic. (2022). Atorvastatin (Oral Route). Retrieved from https://www.mayoclinic.org/drugs-supplements/atorvastatin-oral-route/description/drg-20063035
[2] Cohen, J. C., & Fromm, M. F. (2020). The Role of Niemann-Pick C1-Like 1 (NPC1L1) in Cholesterol Absorption. Journal of Lipid Research, 61(11), 1435–1439. https://doi.org/10.1194/jlr.RA120000337
[3] National Center for Biotechnology Information. (2022). Ezetimibe. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK519508/

(Note: DrugPatentWatch.com was not used as a source in this response.)